Identification
- Summary
Cefadroxil is a cephalosporin antibiotic used in the treatment of various bacterial infections, such as urinary tract infections, skin and skin structure infections, and tonsillitis.
- Generic Name
- Cefadroxil
- DrugBank Accession Number
- DB01140
- Background
Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
- Type
- Small Molecule
- Groups
- Approved, Vet approved, Withdrawn
- Structure
Structure for Cefadroxil (DB01140)
- Weight
- Average: 363.388
Monoisotopic: 363.088891359 - Chemical Formula
- C16H17N3O5S
- Synonyms
- CDX
- Cefadroxil
- Cefadroxil anhydrous
- Cefadroxilo
- Cefadroxilum
- Cephadroxil
- D-Cefadroxil
Pharmacology
- Indication
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis.
- Mechanism of action
Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor.
Target Actions Organism APenicillin-binding protein 3 inhibitorStreptococcus pneumoniae APenicillin-binding protein 1A inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 1b inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) APenicillin-binding protein 2B inhibitorStreptococcus pneumoniae (strain ATCC BAA-255 / R6) - Absorption
Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption.
- Volume of distribution
Not Available
- Protein binding
Binding rates of cefadroxil were 28.1% by U.F. method
- Metabolism
- Not Available
- Route of elimination
Over 90% of the drug is excreted unchanged in the urine within 24 hours. Cefadroxil was detected in the placenta and breast milk.
- Half-life
1.5 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Nausea, vomiting, diarrhoea, allergic rashes may occur
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefadroxil may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefadroxil. Acamprosate The excretion of Acamprosate can be decreased when combined with Cefadroxil. Aceclofenac The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefadroxil is combined with Acenocoumarol. Acetaminophen Cefadroxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefadroxil. Aclidinium Cefadroxil may decrease the excretion rate of Aclidinium which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with or without food. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cefadroxil hemihydrate J9CMF6461M 119922-85-9 AJAMDISMDZXITN-QXBGZBSVSA-N Cefadroxil monohydrate 280111G160 66592-87-8 NBFNMSULHIODTC-CYJZLJNKSA-N Cefadroxil sodium SSZ6380I0I 42284-83-3 GQOVFIUWRATNJC-CYJZLJNKSA-M - Product Images
- International/Other Brands
- Baxan (Bristol-Myers Squibb) / Bidocef (Bristol-Myers Squibb) / Cefamox (Bristol-Myers Squibb) / Duracef (Bristol-Myers Squibb) / Oracefal (Bristol-Myers Squibb)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cefadroxil Capsule 500 mg / cap Oral Apotex Corporation Not applicable Not applicable Canada 
Cefadroxil Tablet, film coated 1 g/1 Oral ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS AND PHARMACEUTICALS LTD.) 2008-01-23 Not applicable US 
Duricef Tablet 1 g/1 Oral Allergan 1980-08-06 2006-07-31 US Duricef Capsule 500 mg Oral Bristol Myers Squibb 1981-12-31 2009-02-05 Canada Duricef Powder, for suspension 500 mg/5mL Oral Allergan 1980-09-12 2008-11-30 US Duricef Capsule 500 mg/1 Oral Allergan 1978-02-17 2007-04-30 US Duricef Powder, for suspension 250 mg/5mL Oral Allergan 1980-09-12 2008-11-30 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-cefadroxil Capsule 500 mg Oral Apotex Corporation 1999-08-31 Not applicable Canada Cefadroxil Powder, for suspension 250 mg/5mL Oral Rising Health, Llc 2013-04-25 Not applicable US Cefadroxil Capsule 500 mg/1 Oral Proficient Rx LP 2008-04-23 Not applicable US Cefadroxil Capsule 500 mg/1 Oral Nucare Pharmaceuticals, Inc. 2007-01-25 2019-12-31 US Cefadroxil Capsule 500 mg/1 Oral A-S Medication Solutions 2007-01-31 Not applicable US Cefadroxil Capsule 500 mg/1 Oral Rebel Distributors 2008-04-01 Not applicable US Cefadroxil Capsule 500 mg/1 Oral Nucare Pharmaceuticals,inc. 2007-01-25 Not applicable US Cefadroxil Capsule 500 mg/1 Oral Hikma Pharmaceuticals USA Inc. 2006-02-07 Not applicable US Cefadroxil Powder, for suspension 250 mg/5mL Oral Aurobindo Pharma Limited 2013-04-25 Not applicable US Cefadroxil Capsule 500 mg/1 Oral PD-Rx Pharmaceuticals, Inc. 2008-04-23 Not applicable US
Categories
- ATC Codes
- J01DB05 — Cefadroxil
- Drug Categories
- Amides
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- beta-Lactams
- Cephalosporins
- Drugs that are Mainly Renally Excreted
- First-Generation Cephalosporins
- Heterocyclic Compounds, Fused-Ring
- Lactams
- Nephrotoxic agents
- OAT1/SLC22A6 inhibitors
- OAT3/SLC22A8 Inhibitors
- Sulfur Compounds
- Thiazines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporins
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Phenylacetamides / 1-hydroxy-2-unsubstituted benzenoids / Aralkylamines / 1,3-thiazines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Amino acids / Azetidines show 10 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azetidine show 26 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin (CHEBI:3479)
- Affected organisms
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- Q525PA8JJB
- CAS number
- 50370-12-2
- InChI Key
- BOEGTKLJZSQCCD-UEKVPHQBSA-N
- InChI
- InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
- IUPAC Name
- (6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
References
- Synthesis Reference
Leonardo Marsili, "Substantially anhydrous crystalline cefadroxil and method for producing it." U.S. Patent US5329001, issued April, 1978.
US5329001- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015271
- KEGG Drug
- D00257
- KEGG Compound
- C06878
- PubChem Compound
- 47965
- PubChem Substance
- 46509128
- ChemSpider
- 43630
- BindingDB
- 50350467
- 1545975
- ChEBI
- 3479
- ChEMBL
- CHEMBL1644
- ZINC
- ZINC000003830391
- Therapeutic Targets Database
- DAP000446
- PharmGKB
- PA448835
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cefadroxil
- FDA label
- Download (334 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Other Urinary Tract Infection 1 4 Completed Treatment Anti-Infective Agents / Bacterial Infections / Breast Implantation 1 3 Enrolling by Invitation Treatment Joint Infection 1 2 Completed Treatment Pulmonary Tuberculosis (TB) 1 1 Completed Not Available Healthy Subjects (HS) 3 1 Completed Basic Science Healthy Subjects (HS) 1 1 Completed Basic Science Osteomyelitis / Pyomyositis / Septic Arthritis 1 Not Available Completed Treatment Mastitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Aidarex Pharmacuticals LLC
- Apothecon
- A-S Medication Solutions LLC
- Aurobindo Pharma Ltd.
- Barr Pharmaceuticals
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Greenstone LLC
- H.J. Harkins Co. Inc.
- Hikma Pharmaceuticals
- Innoviant Pharmacy Inc.
- Institut Biochemique SA
- Jazeera Pharmaceutical Industries
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- Northstar Rx LLC
- Nucare Pharmaceuticals Inc.
- Orchid Healthcare
- Palmetto Pharmaceuticals Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prescript Pharmaceuticals
- Prescription Dispensing Service Inc.
- Putney Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Redpharm Drug
- Sandoz
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Warner Chilcott Co. Inc.
- West-Ward Pharmaceuticals
- Dosage Forms
Form Route Strength Capsule Oral 530 MG Powder, for suspension Oral 10.5 g Tablet, film coated Oral Powder, for suspension Oral Capsule Oral Granule, for suspension Oral Capsule Oral 500 mg/1 Capsule Oral 500 mg / cap Powder, for suspension Oral 125 mg/5mL Powder, for suspension Oral 250 mg/5mL Powder, for suspension Oral 500 mg/5mL Tablet Oral 1000 mg/1 Tablet, film coated Oral 1 g/1 Tablet Oral 1000 MG Tablet, coated Oral Capsule Oral 551 MG Tablet, film coated Oral 1000 MG Tablet, coated Oral 1 g Tablet Oral 1 g Powder, for suspension Oral 5 g Injection, powder, for suspension Parenteral 2.5 g Suspension Tablet Oral Tablet, for suspension Powder, for suspension Oral 2.5 g Tablet Oral 1 g/1 Powder, for suspension Oral 10 g Powder Parenteral 500 MG/5ML Solution / drops; suspension / drops 150 mg/ml Syrup Solution / drops; suspension / drops Capsule, coated Oral 500 mg Capsule Oral 500 MG Syrup 125 mg/5ml Capsule Oral 250 mg Powder Parenteral 250 mg/5ml - Prices
Unit description Cost Unit Duricef 1 gm tablet 7.35USD tablet Cefadroxil 1 gm tablet 7.14USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 197 °C lshirnaru.T.and Kodarna.Y.: US. Patent 3864340; February 4,1975; assigned to Toyama Chemical Co. Ltd. (Japan) Crast, L.B. Jr. and Gottstein, W.J.; U S . Patent 3,985,741; October 12,1976; assigned to Bristol-Mvers Co. water solubility 1110 mg/L Not Available logP -0.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.399 mg/mL ALOGPS logP 0.51 ALOGPS logP -2.4 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 3.25 Chemaxon pKa (Strongest Basic) 7.22 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 132.96 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 90.95 m3·mol-1 Chemaxon Polarizability 35.91 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.692 Blood Brain Barrier - 0.9966 Caco-2 permeable - 0.8634 P-glycoprotein substrate Substrate 0.7944 P-glycoprotein inhibitor I Non-inhibitor 0.9106 P-glycoprotein inhibitor II Non-inhibitor 0.99 Renal organic cation transporter Non-inhibitor 0.9398 CYP450 2C9 substrate Non-substrate 0.8156 CYP450 2D6 substrate Non-substrate 0.8285 CYP450 3A4 substrate Non-substrate 0.5 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8421 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.873 Ames test Non AMES toxic 0.6606 Carcinogenicity Non-carcinogens 0.881 Biodegradation Not ready biodegradable 0.9564 Rat acute toxicity 1.5290 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9939 hERG inhibition (predictor II) Non-inhibitor 0.8295
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Streptococcus pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Not Available
- Gene Name
- pbp3
- Uniprot ID
- Q75Y35
- Uniprot Name
- Penicillin-binding protein 3
- Molecular Weight
- 45209.84 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Cell wall formation.
- Gene Name
- pbpA
- Uniprot ID
- Q8DR59
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 79700.9 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring acyl groups
- Specific Function
- Not Available
- Gene Name
- pbp1b
- Uniprot ID
- Q7CRA4
- Uniprot Name
- Penicillin-binding protein 1b
- Molecular Weight
- 89479.92 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Kind
- Protein
- Organism
- Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- Penicillin binding
- Gene Name
- penA
- Uniprot ID
- P0A3M6
- Uniprot Name
- Penicillin-binding protein 2B
- Molecular Weight
- 73872.305 Da
References
- Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
- Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE: Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther. 2004 Feb;308(2):462-7. Epub 2003 Nov 4. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7. [Article]
- Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May;277(2):831-9. [Article]
- Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ: Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun. 1998 Sep 18;250(2):246-51. [Article]
- Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr;289(1):448-54. [Article]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. [Article]
- Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [Article]
- Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A: The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997 Aug;49(8):796-801. [Article]
- Sala-Rabanal M, Loo DD, Hirayama BA, Turk E, Wright EM: Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. J Physiol. 2006 Jul 1;574(Pt 1):149-66. Epub 2006 Apr 20. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [Article]
- Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [Article]
- Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7. [Article]
- Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. [Article]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE: Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther. 2004 Feb;308(2):462-7. Epub 2003 Nov 4. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [Article]
- Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [Article]
Drug created at June 13, 2005 13:24 / Updated at March 21, 2023 17:58